Beyond therapeutic indication, the market taxonomy further distinguishes montelukast by types of dosage form, each influencing market dynamics through patient adherence and regulatory pathways. The dominant tablet format, typically 10 mg for adults, captures the bulk of volume due to its established manufacturing scale and generic competition. Chewable tablets (4 mg and 5 mg) target pediatric patients, supporting growth in the child‑specific segment where ease of administration drives uptake. Oral suspension offers a liquid alternative for infants and those with swallowing difficulties, albeit at a higher price point, contributing a modest but strategic share. Emerging granule formulations aim to improve bioavailability and reduce dosing frequency, positioning themselves for future market expansion as clinical data accumulate. While precise revenue percentages are proprietary, the hierarchy of dosage forms aligns with the application chart: tablets dominate the asthma cohort, chewables align with pediatric allergic rhinitis, and suspensions support EIB in younger athletes. Understanding these type‑based nuances is essential for forecasting product lifecycle and competitive positioning in the montelukast drug market.
